Alpha Healthcare III (NASDAQ:ALPA) announced this morning that it has signed a non-binding LOI for its combination Carmell Therapeutics to acquire an unnamed commercial-stage biotech firm for about $65 million.
The consideration would come in the form of $8 million in cash and $57 million in combined Carmell stock at close plus $75 million in potential milestone payments paid out along the same split (12% cash and 88% shares). This target company’s shares would be locked for 12 months following close.
The $140 million total potential value of this acquisition comes close to doubling the scale of the initial combination with Carmell, which was struck at $188 million enterprise value. Pittsburgh-based Carmell is developing a treatment platform to accelerate healing in bone fractures and soft tissue wounds.
It could also provide Carmell with some cash flow nearer at hand post-close as the target generated about $5 million in EBITDA from $50 million in revenue during the 12 months ending March 31, 2023.
The target also has a sales contract in place with a purchasing organization with coverage in about 1,500 US hospitals. Carmell’s therapies on the other hand remain at the clinical stage with its most advanced candidates undergoing Phase II trials.
This acquisition agreement remains non-binding, however, and may not come to fruition. In the meantime, it may serve as an amuse-bouche for Alpha Healthcare III investors as they head into a completion vote for the Carmell deal on July 11.
BM Acquisition Corp. (NASDAQ:BMOKU) has filed for a $60 million IPO to bring another first-time, Asia-based team to the market. The new SPAC is serving up 1/2 warrants in each of its units and the team will have 18 months under its initial search window to close a deal. It may extend this, but only...
At the SPAC of Dawn The Fed’s rate decision day has finally come and futures are slightly green in anticipation. De-SPACs have largely opted not to hedge their bets on the event with several making large-scale equity capital raises directly on its eve. Four companies alone raised over $1 billion in secondary offerings this week,...
Pioneer Acquisition I Corp. (NASDAQ:PACHU) announced the pricing of its $220 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “PACHU”, Wednesday, June 18, 2025. The new SPAC aims to combine with a target company in the healthcare sector, which could include medical device manufacturers, digital healthcare firms...
Axiom Intelligence Acquisition Corp. 1 (NASDAQ:AXINU) announced the pricing of its $175 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “AXINU”, Wednesday, June 18, 2025. The new SPAC plans to combine a European infrastructure target company potentially in the energy, digitization or transportation spheres. Axiom 1’s management...
Solarius Capital (NASDAQ:INACU) has filed for a $150 million IPO to seek out a financial services target with a team making its first step into SPACs. The new SPAC is offering investors a 1/2 warrant in each unit and it will overfund its trust to 100.5% with $10.05 per unit in the trust account from...